Mankind Pharma Limited — Updates, 23-01-2025: Press Release

Mankind Pharma reported robust Q3FY25 financial results with revenues of INR 3,230 Cr, reflecting a 24% year-on-year growth. The adjusted EBITDA margin improved to 27.7%, primarily driven by strong performance in the chronic segment and an impressive 30% growth in the OTC business. Domestic revenue rose 17% to INR 2,773 Cr, while exports surged by 121% year-on-year, indicating successful expansion strategies.

In the nine-month period, total revenues reached INR 9,200 Cr, marking a 17% increase, with adjusted EBITDA margin standing at 26.9%. Despite a year-over-year decline of 16% in profit after tax (PAT) to INR 385 Cr, the company’s market share in domestic pharmaceuticals rose from 4.4% to 4.8%, aided by the ongoing integration of BSV and effective brand strategies.

With a consistent focus on chronic and specialty segments, the company is well-positioned for long-term growth, making it a stock worth monitoring for investors seeking opportunities in the healthcare sector.